{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:48:24Z","timestamp":1794008904292,"version":"4.8.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116808","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T03:47:35Z","timestamp":1716781655000},"page":"116808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments"],"prefix":"10.1016","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8243-1530","authenticated-orcid":false,"given":"Mohsen","family":"Nabi-Afjadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samane","family":"Ostadhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Liaghat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Prakash","family":"Pasupulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Masoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Aziziyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Zalpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Abkhooie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahideh","family":"Tarhriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10787-023-01215-y","article-title":"Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients\u2019 susceptibility to COVID-19 to the possible caution of future global diabetes tsunami","volume":"31","author":"Sharbatdar","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib2","doi-asserted-by":"crossref","DOI":"10.4274\/jcrpe.2812","article-title":"Environmental contaminants and pancreatic beta-cells","volume":"8","author":"Fabricio","year":"2016","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/er.2009-0002","article-title":"Endocrine-disrupting chemicals: an Endocrine Society scientific statement","volume":"30","author":"Diamanti-Kandarakis","year":"2009","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/ijerph18020716","article-title":"Bisphenol A and type 2 diabetes mellitus: a review of epidemiologic, functional, and early life factors","volume":"18","author":"Farrugia","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.biopha.2024.116808_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.emcon.2020.07.005","article-title":"Exposure to bisphenol A and risk of developing type 2 diabetes: A mini review","volume":"6","author":"Siddique","year":"2020","journal-title":"Emerg. Contam."},{"key":"10.1016\/j.biopha.2024.116808_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijheh.2021.113865","article-title":"Exposure to the pesticide DDT and risk of diabetes and hypertension: Systematic review and meta-analysis of prospective studies","volume":"239","author":"Hern\u00e1ndez-Mariano","year":"2022","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"10.1016\/j.biopha.2024.116808_bib7","first-page":"1","article-title":"Why does the immune system destroy pancreatic \u03b2-cells but not \u03b1-cells in type 1 diabetes?","author":"Eizirik","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12958-021-00794-1","article-title":"Evaluation of testicular glycogen storage, FGF21 and LDH expression and physiological parameters of sperm in hyperglycemic rats treated with hydroalcoholic extract of Securigera securidaca seeds, and Glibenclamide","volume":"19","author":"Babaei","year":"2021","journal-title":"Reprod. Biol. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1900\/RDS.2021.17.1","article-title":"Molecular mechanisms involved in intrarenal renin-angiotensin and alternative pathways in diabetic nephropathy-a review","volume":"17","author":"Bahreini","year":"2021","journal-title":"Rev. Diabet. Stud."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/ds18-0091","article-title":"A clinical overview of insulin pump therapy for the management of diabetes: past, present, and future of intensive therapy","volume":"32","author":"Berget","year":"2019","journal-title":"Diabetes Spectr.: a Publ. Am. Diabetes Assoc."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1932296817691303","article-title":"Oral insulin delivery in a physiologic context","volume":"11","author":"Arbit","year":"2017","journal-title":"J. Diabetes Sci. Technol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116808_bib12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/jphp.12607","article-title":"Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities","volume":"68","author":"Wong","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116808_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40618-015-0326-3","article-title":"Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis","volume":"39","author":"Akbari","year":"2016","journal-title":"J. Endocrinol. Investig."},{"issue":"6","key":"10.1016\/j.biopha.2024.116808_bib14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/dc09-1807","article-title":"Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes","volume":"33","author":"Kapitza","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jphp.12852","article-title":"Oral insulin delivery: existing barriers and current counter-strategies","volume":"70","author":"Gedawy","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116808_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijbiomac.2022.03.144","article-title":"An overview of oral insulin delivery strategies (OIDS)","volume":"208","author":"Iyer","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ddr.21903","article-title":"Novel strategies to oral delivery of insulin: Current progress of nanocarriers for diabetes management","volume":"83","author":"Abdel-Moneim","year":"2022","journal-title":"Drug Dev. Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/0250-474X.42968","article-title":"Recent challenges in insulin delivery systems: a review","volume":"70","author":"Al-Tabakha","year":"2008","journal-title":"Indian J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1152\/physrev.00021.2017","article-title":"Food intake and eating behavior after bariatric surgery","volume":"98","author":"Al-Najim","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2024.116808_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.physbeh.2013.02.006","article-title":"Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli","volume":"112","author":"Z\u00fcger","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2024.116808_bib21","first-page":"57","article-title":"Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus","author":"Ojha","year":"2019","journal-title":"Clin. Pharmacol.: Adv. Appl."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/jdi.13962","article-title":"Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation","volume":"14","author":"Alsalim","year":"2023","journal-title":"J. Diabetes Investig."},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib23","first-page":"145","article-title":"Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control","volume":"38","author":"McCall","year":"2013","journal-title":"Minerva Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7570\/jomes21071","article-title":"le Roux CW: Amylin as a future obesity treatment","volume":"30","author":"Dehestani","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"issue":"6","key":"10.1016\/j.biopha.2024.116808_bib25","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-21-1261","article-title":"Therapy of endocrine disease: Amylin and calcitonin\u2013physiology and pharmacology","volume":"186","author":"Mathiesen","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.biopha.2024.116808_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170366","article-title":"Amylin brain circuitry","volume":"132","author":"Boccia","year":"2020","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib27","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41386-018-0309-0","article-title":"A novel GPR55-mediated satiety signal in the oval bed nucleus of the stria terminalis","volume":"44","author":"Hawken","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.physbeh.2004.01.006","article-title":"Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats","volume":"81","author":"Mollet","year":"2004","journal-title":"Physiol. Behav."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib29","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/ijo.2009.13","article-title":"Control of food intake and energy expenditure by amylin\u2014therapeutic implications.","volume":"33","author":"Lutz","year":"2009","journal-title":"Int. J. Obes."},{"issue":"5","key":"10.1016\/j.biopha.2024.116808_bib30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2337\/db17-1347","article-title":"Amylin selectively signals onto POMC neurons in the arcuate nucleus of the hypothalamus","volume":"67","author":"Lutz","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2024.116808_bib31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fnagi.2014.00186","article-title":"Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?","volume":"6","author":"Qiu","year":"2014","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1476-5381.2011.01537.x","article-title":"GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities","volume":"166","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4314\/ejst.v10i1.5","article-title":"Correlates of time to microvascular complications among diabetes mellitus patients using parametric and non-parametric approaches: a case study of Ayder referral hospital, Ethiopia","volume":"10","author":"Berihun","year":"2017","journal-title":"Ethiop. J. Sci. Technol."},{"key":"10.1016\/j.biopha.2024.116808_bib34","unstructured":"IDF: Report of non-commncaiable disease. In.; 2015.."},{"key":"10.1016\/j.biopha.2024.116808_bib35","doi-asserted-by":"crossref","DOI":"10.4103\/2277-9175.182213","article-title":"Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population","volume":"5","author":"Sadeghpour","year":"2016","journal-title":"Adv. Biomed. Res."},{"issue":"5","key":"10.1016\/j.biopha.2024.116808_bib36","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2337\/dc12-0958","article-title":"Predicting macro-and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study\/the Japanese Elderly Diabetes Intervention Trial risk engine","volume":"36","author":"Tanaka","year":"2013","journal-title":"Diabetes care"},{"key":"10.1016\/j.biopha.2024.116808_bib37","first-page":"505","article-title":"Prevalence of micro and macrovascular complications and their risk factors in type-2 diabetes mellitus","volume":"62","author":"Agrawal","year":"2014","journal-title":"JAPI"},{"issue":"5","key":"10.1016\/j.biopha.2024.116808_bib38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.4103\/1319-2442.164602","article-title":"Diabetic kidney disease and vascular comorbidities in patients with type 2 diabetes mellitus in a developing country","volume":"26","author":"Bentata","year":"2015","journal-title":"Saudi J. Kidney Dis. Transplant."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-018-0280-0","article-title":"Predictors of vascular complications among type 2 diabetes mellitus patients at University of Gondar Referral Hospital: a retrospective follow-up study","volume":"18","author":"Wolde","year":"2018","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.biopha.2024.116808_bib40","volume":"2017","author":"Marathe","year":"2017"},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.47102\/annals-acadmedsg.V39N7p525","article-title":"Peripheral arterial disease in community-based patients with diabetes in Singapore: results from a primary healthcare study","volume":"39","author":"Narayanan","year":"2010","journal-title":"Ann. Acad. Med. Singap."},{"key":"10.1016\/j.biopha.2024.116808_bib42","doi-asserted-by":"crossref","unstructured":"Litwak L.G.S.-Y., Hussein Z., Malek R., Prusty V., Khamseh M.E. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A 1 chieve study. Diabetology & metabolic syndrome. 2013;5:1-10., Leon, Goh S-Y, Hussein Z, Malek R, Prusty V, Khamseh ME: Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A 1 chieve study. Diabetology & metabolic syndrome 2013, 5:1-10.","DOI":"10.1186\/1758-5996-5-57"},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib43","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/HJH.0000000000000221","article-title":"European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring","volume":"32","author":"Parati","year":"2014","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1464-5491.2004.01115.x","article-title":"WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes","volume":"21","author":"Marchesini","year":"2004","journal-title":"Diabet. Med."},{"issue":"9","key":"10.1016\/j.biopha.2024.116808_bib45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/1060028017710481","article-title":"SGLT-2 inhibitors: is there a role in type 1 diabetes mellitus management?","volume":"51","author":"Ahmed-Sarwar","year":"2017","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4158\/EP15869.RA","article-title":"The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes","volume":"22","author":"Bode","year":"2016","journal-title":"Endocr. Pract."},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib47","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes care"},{"issue":"5","key":"10.1016\/j.biopha.2024.116808_bib49","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves \u03b2-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes care"},{"issue":"21","key":"10.1016\/j.biopha.2024.116808_bib50","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/ajhp\/zxz179","article-title":"Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus","volume":"76","author":"Guyton","year":"2019","journal-title":"Am. J. Health-Syst. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2024.116808_bib51","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/biomedicines9101360","article-title":"Reno-protective effect of GLP-1 receptor agonists in type1 diabetes: dual action on TRPC6 and NADPH oxidases","volume":"9","author":"Youssef","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/life12010029","article-title":"Role of a dual glucose-dependent insulinotropic peptide (GIP)\/glucagon-like peptide-1 receptor agonist (twincretin) in glycemic control: from pathophysiology to treatment","volume":"12","author":"Pelle","year":"2021","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib53","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41467-022-28826-3","article-title":"Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes","volume":"13","author":"Xu","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib54","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/db11-0955","article-title":"Preventing \u03b2-cell loss and diabetes with calcium channel blockers","volume":"61","author":"Xu","year":"2012","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib55","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clim.2009.04.007","article-title":"Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years","volume":"132","author":"Herold","year":"2009","journal-title":"Clin. Immunol."},{"issue":"4748","key":"10.1016\/j.biopha.2024.116808_bib56","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2012.13711","article-title":"Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases","volume":"142","author":"Dean","year":"2012","journal-title":"Swiss Med. Wkly."},{"issue":"22","key":"10.1016\/j.biopha.2024.116808_bib57","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib58","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/dc13-0626","article-title":"B-lymphocyte depletion with rituximab and \u03b2-cell function: two-year results","volume":"37","author":"Pescovitz","year":"2014","journal-title":"Diabetes care"},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib59","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/13543784.2020.1727885","article-title":"CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes","volume":"29","author":"Rachid","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2024.116808_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.716692","article-title":"Therapeutic strategies for diabetes: immune modulation in pancreatic \u03b2 cells","volume":"12","author":"Jo","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2337\/dc22-0908","article-title":"Two-year follow-up from the T1GER study: continued off-therapy metabolic improvements in children and young adults with new-onset T1D treated with golimumab and characterization of responders","volume":"46","author":"Rigby","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2024.116808_bib62","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1007\/s00125-009-1381-0","article-title":"Development of type 1 diabetes in a patient treated with anti-TNF-\u03b1 therapy for active rheumatoid arthritis","volume":"52","author":"Tack","year":"2009","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib63","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/dc09-0054","article-title":"Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study","volume":"32","author":"Mastrandrea","year":"2009","journal-title":"Diabetes care"},{"key":"10.1016\/j.biopha.2024.116808_bib64","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00125-009-1371-2","article-title":"GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes","volume":"52","author":"Agardh","year":"2009","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: Current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2024.116808_bib66","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1159\/000524866","article-title":"Recent advances in immune-based therapies for type 1 diabetes","volume":"96","author":"Smigoc Schweiger","year":"2023","journal-title":"Horm. Res. Paediatr."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the treatment of cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"issue":"12","key":"10.1016\/j.biopha.2024.116808_bib68","doi-asserted-by":"crossref","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13073-024-01300-z","article-title":"Systematic immune cell dysregulation and molecular subtypes revealed by single-cell RNA-seq of subjects with type 1 diabetes","volume":"16","author":"Honardoost","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.biopha.2024.116808_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.751701","article-title":"Insights from single cell RNA sequencing into the immunology of type 1 diabetes-cell phenotypes and antigen specificity","volume":"12","author":"Hanna","year":"2021","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116808_bib71","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2337\/dc23-0675","article-title":"Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves \u03b2-Cell Function","volume":"46","author":"Herold","year":"2023","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.biopha.2024.116808_bib72","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib73","doi-asserted-by":"crossref","first-page":"e935","DOI":"10.1210\/clinem\/dgab816","article-title":"Autoantibodies to N-terminally truncated GAD65 (96-585): HLA associations and predictive value for type 1 diabetes","volume":"107","author":"P\u00f6ll\u00e4nen","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"115","key":"10.1016\/j.biopha.2024.116808_bib74","first-page":"213","article-title":"B cell targeted immunotherapy for type 1 diabetes: What can make it work?","volume":"21","author":"Hamad ARA","year":"2016","journal-title":"Discov. Med."},{"issue":"9","key":"10.1016\/j.biopha.2024.116808_bib75","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Low-dose anti-thymocyte globulin (ATG) preserves \u03b2-cell function and improves HbA1c in new-onset type 1 diabetes","volume":"41","author":"Haller","year":"2018","journal-title":"Diabetes care"},{"issue":"6","key":"10.1016\/j.biopha.2024.116808_bib76","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/db19-0057","article-title":"Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year clinical trial data","volume":"68","author":"Haller","year":"2019","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.biopha.2024.116808_bib77","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/srep45312","article-title":"Tissue resident memory T cells in the human conjunctiva and immune signatures in human dry eye disease","volume":"7","author":"Bose","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116808_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101565","article-title":"Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other","volume":"64","author":"Scherm","year":"2022","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrendo.2009.275","article-title":"Immune therapy for type 1 diabetes mellitus\u2014what is unique about anti-CD3 antibodies?","volume":"6","author":"Chatenoud","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1122","article-title":"Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets","volume":"9","author":"Lu","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clim.2013.02.003","article-title":"Anti-cytokine therapies in T1D: concepts and strategies","volume":"149","author":"Nepom","year":"2013","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib83","doi-asserted-by":"crossref","first-page":"7324","DOI":"10.1038\/s41467-022-34162-3","article-title":"Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib84","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2183\/pjab.86.717","article-title":"Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir","volume":"86","author":"Hirano","year":"2010","journal-title":"Proc. Jpn. Acad., Ser. B"},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib86","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2016.12.74","article-title":"IL-6 and type 1 diabetes mellitus: T cell responses and increase in IL-6 receptor surface expression","volume":"5","author":"Gomes","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.biopha.2024.116808_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108320","article-title":"IL-6 is present in beta and alpha cells in human pancreatic islets: Expression is reduced in subjects with type 1 diabetes","volume":"211","author":"Rajendran","year":"2020","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib88","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/jdi.13706","article-title":"Development of type 1 diabetes in a patient treated with anti-interleukin-6 receptor antibody for rheumatoid arthritis","volume":"13","author":"Kawasaki","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.biopha.2024.116808_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1157265","article-title":"Evaluation of plasma IL-21 as a potential biomarker for type 1 diabetes progression","volume":"14","author":"Schroderus","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib90","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/db10-1157","article-title":"Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models","volume":"60","author":"McGuire","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2024.116808_bib91","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00125-021-05398-3","article-title":"Current and future therapies for type 1 diabetes","volume":"64","author":"von Scholten","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2024.116808_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101417","article-title":"Modeling human T1D-associated autoimmune processes","volume":"56","author":"Khosravi-Maharlooei","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2024.116808_bib93","article-title":"Revisiting the Antigen-Presenting function of \u03b2 Cells in T1D Pathogenesis","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4161\/hv.7.1.12848","article-title":"Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes","volume":"7","author":"Johnson","year":"2011","journal-title":"Hum. Vaccin."},{"issue":"10","key":"10.1016\/j.biopha.2024.116808_bib95","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4239\/wjd.v11.i10.400","article-title":"Type 1 diabetes mellitus and its oral tolerance therapy","volume":"11","author":"Mao","year":"2020","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib96","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/ijms23010390","article-title":"Potential therapeutic application of regulatory T cells in diabetes mellitus type 1","volume":"23","author":"Ben-Skowronek","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116808_bib97","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00125-016-4125-y","article-title":"Immunogenicity of human embryonic stem cell-derived beta cells","volume":"60","author":"van der Torren","year":"2017","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib98","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/cells9020283","article-title":"Stem cell therapy for diabetes: beta cells versus pancreatic progenitors","volume":"9","author":"Memon","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib99","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell stem Cell"},{"issue":"5","key":"10.1016\/j.biopha.2024.116808_bib100","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gt.2015.18","article-title":"\u03b2-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection","volume":"22","author":"El Khatib","year":"2015","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib101","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.mt.6300190","article-title":"The suicide gene therapy challenge: how to improve a successful gene therapy approach","volume":"15","author":"Bonini","year":"2007","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2024.116808_bib102","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/mt.2015.100","article-title":"An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells","volume":"23","author":"Yagyu","year":"2015","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib103","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.stemcr.2019.01.012","article-title":"A double fail-safe approach to prevent tumorigenesis and select pancreatic \u03b2 cells from human embryonic stem cells","volume":"12","author":"Qadir","year":"2019","journal-title":"Stem Cell Rep."},{"issue":"7733","key":"10.1016\/j.biopha.2024.116808_bib104","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-018-0733-7","article-title":"Linking a cell-division gene and a suicide gene to define and improve cell therapy safety","volume":"563","author":"Liang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116808_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.57","article-title":"Escape mutations, ganciclovir resistance, and teratoma formation in human iPSCs expressing an HSVtk suicide gene","volume":"5","author":"Kotini","year":"2016","journal-title":"Mol. Ther. -Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.116808_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.3","article-title":"Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch","volume":"3","author":"Yagyu","year":"2016","journal-title":"Mol. Ther. -Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib107","first-page":"589","article-title":"Human embryonic stem cells: derivation, culture, and differentiation: a review","volume":"28","author":"Vazin","year":"2010","journal-title":"Restor. Neurol. Neurosci."},{"issue":"11","key":"10.1016\/j.biopha.2024.116808_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111390","article-title":"Comparison of surface markers between human and rabbit mesenchymal stem cells","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.biopha.2024.116808_bib109","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/cells8080886","article-title":"Mesenchymal stem cells for regenerative medicine","volume":"8","author":"Han","year":"2019","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.biopha.2024.116808_bib110","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.2337\/db11-1141","article-title":"Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity","volume":"61","author":"Si","year":"2012","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib111","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang","year":"2020","journal-title":"Cell Prolif."},{"issue":"9","key":"10.1016\/j.biopha.2024.116808_bib112","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1177\/0963689718779777","article-title":"Role of insulin-like growth factor 1 receptor signaling in stem cell stemness and therapeutic efficacy","volume":"27","author":"Teng","year":"2018","journal-title":"Cell Transplant."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib113","first-page":"82","article-title":"A review of clinical trials: mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus","volume":"7","author":"Cho","year":"2018","journal-title":"Am. J. stem Cells"},{"key":"10.1016\/j.biopha.2024.116808_bib114","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8637493","article-title":"Mesenchymal stem cells (MSCs): a novel therapy for type 2 diabetes","volume":"2022","author":"Gao","year":"2022","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.biopha.2024.116808_bib115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00125-004-1606-1","article-title":"In vitro generation of insulin-producing beta cells from adult exocrine pancreatic cells","volume":"48","author":"Baeyens","year":"2005","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib116","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13287-022-02977-y","article-title":"Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges","volume":"13","author":"Silva IBB","year":"2022","journal-title":"Stem Cell Res. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.116808_bib117","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2337\/db12-0167","article-title":"Factors expressed by murine embryonic pancreatic mesenchyme enhance generation of insulin-producing cells from hESCs","volume":"62","author":"Guo","year":"2013","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.biopha.2024.116808_bib118","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.7150\/ijms.87472","article-title":"Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances","volume":"20","author":"Li","year":"2023","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-01977-0","article-title":"NKX6. 1 transcription factor: a crucial regulator of pancreatic \u03b2 cell development, identity, and proliferation","volume":"11","author":"Aigha","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biopha.2024.116808_bib120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11427-006-2016-z","article-title":"Expression of Pdx-1 in bone marrow mesenchymal stem cells promotes differentiation of islet-like cells in vitro","volume":"49","author":"Sun","year":"2006","journal-title":"Sci. China Ser. C: Life Sci."},{"issue":"5","key":"10.1016\/j.biopha.2024.116808_bib121","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s11033-022-07194-7","article-title":"Differentiation of multipotent stem cells to insulin-producing cells for treatment of diabetes mellitus: Bone marrow-and adipose tissue-derived cells comparison","volume":"49","author":"Eydian","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2024.116808_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.103542","article-title":"Mapping global trends in adipose-derived mesenchymal stem cell research: A bibliometric analysis using scopus database","volume":"77","author":"Sharun","year":"2022","journal-title":"Ann. Med. Surg."},{"issue":"8","key":"10.1016\/j.biopha.2024.116808_bib123","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/clinem\/dgad142","article-title":"Adipose-derived mesenchymal stem cells therapy as a new treatment option for diabetes mellitus","volume":"108","author":"Mik\u0142osz","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2024.116808_bib124","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cmet.2021.03.019","article-title":"Insulin action in adipocytes, adipose remodeling, and systemic effects","volume":"33","author":"Santoro","year":"2021","journal-title":"Cell Metab."},{"issue":"14","key":"10.1016\/j.biopha.2024.116808_bib125","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3390\/cells11142145","article-title":"Pancreatic transdifferentiation using \u03b2-cell transcription factors for type 1 diabetes treatment","volume":"11","author":"Mahoney","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.biopha.2024.116808_bib126","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/biology10060539","article-title":"Transdifferentiation of human fibroblasts into skeletal muscle cells: Optimization and assembly into engineered tissue constructs through biological ligands","volume":"10","author":"Abdel-Raouf","year":"2021","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib127","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/scd.2016.0174","article-title":"Direct conversion through trans-differentiation: efficacy and safety","volume":"26","author":"Prasad","year":"2017","journal-title":"Stem Cells Dev."},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib128","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.bbamcr.2017.04.017","article-title":"Transdifferentiation and reprogramming: overview of the processes, their similarities and differences","volume":"1864","author":"Cie\u015blar-Pobuda","year":"2017","journal-title":"Biochim. Et. Biophys. Acta (BBA)-Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib129","first-page":"1","article-title":"Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX6. 1","volume":"9","author":"Memon","year":"2018","journal-title":"Stem Cell Res. Ther."},{"issue":"15","key":"10.1016\/j.biopha.2024.116808_bib130","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.2015.2928","article-title":"Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial","volume":"313","author":"Bonifacio","year":"2015","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib131","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1517\/17425247.2016.1107543","article-title":"Oral insulin delivery systems using chitosan-based formulation: a review","volume":"13","author":"Al Rubeaan","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib132","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-021-01418-2","article-title":"100 years of insulin: celebrating the past, present and future of diabetes therapy","volume":"27","author":"Sims","year":"2021","journal-title":"Nat. Med."},{"issue":"1-2","key":"10.1016\/j.biopha.2024.116808_bib133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2018.02.045","article-title":"Oral insulin delivery, the challenge to increase insulin bioavailability: Influence of surface charge in nanoparticle system","volume":"542","author":"Czuba","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"19","key":"10.1016\/j.biopha.2024.116808_bib134","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2017.17070","article-title":"Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial","volume":"318","author":"Krischer","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2024.116808_bib135","article-title":"Encapsulation of an insulin-modified phosphatidylcholine complex in a self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin delivery","volume":"57","author":"Bravo-Alfaro","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116808_bib136","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.3390\/life13101955","article-title":"The Brain Endothelial Cell Glycocalyx Plays a Crucial Role in the Development of Enlarged Perivascular Spaces in Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus","volume":"13","author":"Hayden","year":"2023","journal-title":"Life"},{"issue":"7","key":"10.1016\/j.biopha.2024.116808_bib137","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1128\/IAI.01681-14","article-title":"Epithelial microvilli establish an electrostatic barrier to microbial adhesion","volume":"82","author":"Bennett","year":"2014","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2024.116808_bib138","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fcimb.2020.00248","article-title":"The role of the gastrointestinal mucus system in intestinal homeostasis: implications for neurological disorders","volume":"10","author":"Herath","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116808_bib139","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.4155\/tde.14.67","article-title":"Pathways and progress in improving drug delivery through the intestinal mucosa and blood\u2013brain barriers","volume":"5","author":"Laksitorini","year":"2014","journal-title":"Ther. Deliv."},{"issue":"2-3","key":"10.1016\/j.biopha.2024.116808_bib140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0169-409X(98)00075-1","article-title":"Oral insulin delivery","volume":"35","author":"Carino","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2024.116808_bib141","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10611860903302815","article-title":"Design of oral insulin delivery systems","volume":"18","author":"Wong","year":"2010","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib142","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1463-1326.2009.01150.x","article-title":"Oral insulin\u2013a review of current status","volume":"12","author":"Iyer","year":"2010","journal-title":"Diabetes, Obes. Metab."},{"issue":"28","key":"10.1016\/j.biopha.2024.116808_bib143","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1021\/acsami.5b03555","article-title":"N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption","volume":"7","author":"Sheng","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib144","first-page":"1057","article-title":"Novel approaches for oral delivery of insulin and current status of oral insulin products","volume":"3","author":"VP","year":"2010","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"key":"10.1016\/j.biopha.2024.116808_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107537","article-title":"Approaches to improve intestinal and transmucosal absorption of peptide and protein drugs","volume":"211","author":"Yamamoto","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.116808_bib146","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jfda.2015.01.007","article-title":"Application of polymeric nanoparticles and micelles in insulin oral delivery","volume":"23","author":"Alai","year":"2015","journal-title":"J. Food Drug Anal."},{"issue":"1","key":"10.1016\/j.biopha.2024.116808_bib147","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s11658-022-00377-x","article-title":"Exosome application in treatment and diagnosis of B-cell disorders: leukemias, multiple sclerosis, and arthritis rheumatoid","volume":"27","author":"Karami Fath","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.biopha.2024.116808_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105412","article-title":"Drug delivery systems based on nanoparticles and related nanostructures","volume":"151","author":"Nikezi\u0107","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2024.116808_bib149","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.toxrep.2019.04.004","article-title":"Role of nanostructures in improvising oral medicine","volume":"6","author":"Ghosh","year":"2019","journal-title":"Toxicol. Rep."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2026.119714","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000}},{"DOI":"10.1016\/j.biopha.2026.119714","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:02:35Z","timestamp":1781650955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224006929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":149,"alternative-id":["S0753332224006929"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116808","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116808"}}